PD-1/PD-L1 Inhibitor C1 - CAS# 1675201-83-8 size:10 mg solid resulting in a water-soluble compound

resulting in a water-soluble compound

INCB024360 has completed Phase I clinical trials and is now being used in combination with other cancer immunotherapy agents

Formula: C22H20ClF3N4O3S

2109424-53-3 (SAG(trans-cis) HCl)

Enhances CRISPR-Cas9-mediated HER2 mutation frequency

PD-1/PD-L1 Inhibitor C1 - CAS# 1675201-83-8 size:10 mg solid resulting in a water-soluble compoundPD 1 PD L1 inhibitor C1, CAS No. 1675201 83 8, is a potent and selective small molecule inhibitor of the PD 1 PD L1 protein protein interactions with IC50 < 100 nM (PD 1 PD L1 Homogenous Time Resolved Fluorescence (HTRF) binding assay). It may potentially be useful in the treatment of cancer as well as infectious diseases such as hepatitis C. The programmed death 1 programmed death ligand 1 (PD 1 PD L1) interaction plays a dominant role in the